These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 26982462)

  • 1. Dengue vaccine: an update on recombinant subunit strategies.
    Martin J; Hermida L
    Acta Virol; 2016 Mar; 60(1):3-14. PubMed ID: 26982462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Developments in Recombinant Protein-Based Dengue Vaccines.
    Tripathi NK; Shrivastava A
    Front Immunol; 2018; 9():1919. PubMed ID: 30190720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.
    Lauretti F; Chattopadhyay A; de Oliveira França RF; Castro-Jorge L; Rose J; Fonseca BA
    Hum Vaccin Immunother; 2016 Sep; 12(9):2327-33. PubMed ID: 27185081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in dengue vaccine development.
    Raviprakash K; Defang G; Burgess T; Porter K
    Hum Vaccin; 2009 Aug; 5(8):520-8. PubMed ID: 19535912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.
    Coller BA; Clements DE; Bett AJ; Sagar SL; Ter Meulen JH
    Vaccine; 2011 Sep; 29(42):7267-75. PubMed ID: 21777637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dengue vaccine development by the year 2020: challenges and prospects.
    Wilder-Smith A
    Curr Opin Virol; 2020 Aug; 43():71-78. PubMed ID: 33086187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence.
    Sun J; Li M; Wang Y; Hao P; Jin X
    Vaccine; 2017 Nov; 35(46):6308-6320. PubMed ID: 28987441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus.
    Lazo L; Izquierdo A; Suzarte E; Gil L; Valdés I; Marcos E; Álvarez M; Romero Y; Guzmán MG; Guillén G; Hermida Cruz L
    Microbiol Immunol; 2014 Apr; 58(4):219-26. PubMed ID: 24689365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A molecular evaluation of dengue virus pathogenesis and its latest vaccine strategies.
    Faheem M; Raheel U; Riaz MN; Kanwal N; Javed F; us Sahar Sadaf Zaidi N; Qadri I
    Mol Biol Rep; 2011 Aug; 38(6):3731-40. PubMed ID: 21107723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current progress in dengue vaccines.
    Wan SW; Lin CF; Wang S; Chen YH; Yeh TM; Liu HS; Anderson R; Lin YS
    J Biomed Sci; 2013 Jun; 20(1):37. PubMed ID: 23758699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel immunization approach for dengue infection based on conserved T cell epitopes formulated in calcium phosphate nanoparticles.
    Huang X; Karabudak A; Comber JD; Philip M; Morcol T; Philip R
    Hum Vaccin Immunother; 2017 Nov; 13(11):2612-2625. PubMed ID: 28933657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Research progress in the structure and function of dengue virus non-structural 1 protein].
    Chen Y; Ren RW; Liu JW
    Bing Du Xue Bao; 2014 Nov; 30(6):683-8. PubMed ID: 25868284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of dengue virus and the development of a vaccine.
    Murrell S; Wu SC; Butler M
    Biotechnol Adv; 2011; 29(2):239-47. PubMed ID: 21146601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates.
    Chen HW; Liu SJ; Li YS; Liu HH; Tsai JP; Chiang CY; Chen MY; Hwang CS; Huang CC; Hu HM; Chung HH; Wu SH; Chong P; Leng CH; Pan CH
    Arch Virol; 2013 Jul; 158(7):1523-31. PubMed ID: 23456422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dengue vaccine candidates in development.
    Durbin AP; Whitehead SS
    Curr Top Microbiol Immunol; 2010; 338():129-43. PubMed ID: 19802583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent progress in dengue vaccine development.
    Wei J; Chen H; An J
    Virol Sin; 2014 Dec; 29(6):353-63. PubMed ID: 25547681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focused dengue vaccine development: outwitting nature's design.
    Kudlacek ST; Metz SW
    Pathog Dis; 2019 Feb; 77(1):. PubMed ID: 30726906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.
    Bischof GF; Magnani DM; Ricciardi M; Shin YC; Domingues A; Bailey VK; Gonzalez-Nieto L; Rakasz EG; Watkins DI; Desrosiers RC
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28592531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next generation dengue vaccines: a review of candidates in preclinical development.
    Schmitz J; Roehrig J; Barrett A; Hombach J
    Vaccine; 2011 Sep; 29(42):7276-84. PubMed ID: 21781998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.